Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 184.35% | -28.44% | -18.37% | -44.55% | -56.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.35% | -28.44% | -18.37% | -44.55% | -56.47% |
| Cost of Revenue | 139.91% | 396.94% | 873.06% | 408.80% | 292.77% |
| Gross Profit | -136.72% | -677.01% | -13,190.70% | -1,738.89% | -825.76% |
| SG&A Expenses | 78.02% | 29.93% | 117.74% | 61.53% | 105.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.52% | 230.01% | 469.97% | 259.32% | 212.71% |
| Operating Income | -119.40% | -301.40% | -845.74% | -483.70% | -355.04% |
| Income Before Tax | 67.84% | 13.37% | -984.00% | -550.03% | -2,932.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.84% | 13.37% | -984.00% | -550.03% | -2,932.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.84% | 13.37% | -984.00% | -550.03% | -2,932.60% |
| EBIT | -119.40% | -301.40% | -845.74% | -483.70% | -355.04% |
| EBITDA | -118.08% | -302.54% | -859.86% | -484.41% | -361.23% |
| EPS Basic | 79.13% | 41.01% | -119.69% | -32.29% | -616.75% |
| Normalized Basic EPS | -54.07% | -204.34% | -88.45% | -9.17% | 2.92% |
| EPS Diluted | 79.13% | 40.84% | -119.69% | -32.29% | -616.75% |
| Normalized Diluted EPS | -54.07% | -204.34% | -88.45% | -9.17% | 2.92% |
| Average Basic Shares Outstanding | 54.06% | 46.85% | 393.39% | 391.37% | 323.10% |
| Average Diluted Shares Outstanding | 54.06% | 46.85% | 393.39% | 391.37% | 323.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |